semaglutide and cardiovascular outcomes in obesity without diabetes 2.4 mg delivered a statistically significant 20% risk reduction major adverse events – REGENHEALTHSOLUTIONS (RHS) SELECT Trial

GLP-1 receptor agonists may be appropriate for individuals who: Have a body mass index (BMI) of 35 kg/m or higher (or lower thresholds32.5 kg/m or abovefor people from Black, Asian, and other minority ethnic groups) and would benefit from weight loss Have established cardiovascular disease or are at high cardiovascular risk (certain GLP-1 receptor agonists have demonstrated cardiovascular benefits in clinical trials) Have chronic kidney disease (CKD) or heart failure, where specific agents may offer additional protection Require additional glucose-lowering therapy but wish to avoid weight gain associated with some other diabetes medicines Cannot tolerate or have contraindications to other glucose-lowering therapies NICE NG28 continuation criteria : GLP-1 receptor agonist therapy should be continued beyond 6 months only if the person has had a beneficial metabolic response , defined as a reduction of at least 11 mmol/mol (1.0%) in HbA1c and a weight loss of at least 3% of initial body weight

Glucagon-like peptide-1: A multi-faceted anti-inflammatory agent

doi:10.1017/s1481803500011143

Patients with Crohns disease-an autoimmune disorder of digestive tract showed a reduction in Faecalibacterium and Roseburia spp

The following tables describe how many clicks can deliver how much dosage when using standard semaglutide pens: Semaglutide multi-dose pen (0.25/0.5 mg) Semaglutide multi-dose pen (1 mg) Semaglutide multi-dose pen (2 mg) Additionally, some compounding pharmacies offer compounded semaglutide with microdoses